Relapsed and refractory aggressive NHL: Time for a change

Transfusion and Apheresis Science

Volumn 49, Issue 1, 2013, Pages 72-79

  Gangatharan, Shane ^a   Kuruvilla, John ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; EVEROLIMUS; FOSTAMATINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; IFOSFAMIDE; INOTUZUMAB OZOGAMICIN; LENALIDOMIDE; MELPHALAN; MOCETINOSTAT; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PREDNISOLONE; RITUXIMAB; TEMSIROLIMUS; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ADD ON THERAPY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CLINICAL FEATURE; HUMAN; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; REVIEW; SALVAGE THERAPY; T CELL LYMPHOMA; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, NON-HODGKIN; RECURRENCE; TREATMENT FAILURE;

EID: 84882944244     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2013.05.029     Document Type: Review

References (66)

1. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
2. Telio D., Fernandes K., Ma C., Tsang R., Keating A., Crump M., et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2012, 53:836-841.
3. Sehn L.H., Donaldson J., Chhanabhai M., Fitzgerald C., Gill K., Klasa R., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23:5027-5033.
4. Pfreundschuh M., Kuhnt E., Trumper L., Osterborg A., Trneny M., Shepherd L., et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) group. Lancet Oncol 2011, 12:1013-1022.
5. Pfreundschuh M., Schubert J., Ziepert M., Schmits R., Mohren M., Lengfelder E., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
6. Coiffier B., Thieblemont C., Van Den Neste E., Lepeu G., Plantier I., Castaigne S., et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
7. Shipp M.A., Harrington D.P., Anderson J.R., Armitage J.O., Bonadonna G., Brittinger G., et al. A predictive model for aggressive non-Hodgkin's lymphoma. The international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993, 329:987-994.
8. Sehn L.H., Berry B., Chhanabhai M., Fitzgerald C., Gill K., Hoskins P., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109:1857-1861.
9. Vose J.M., Zhang M.J., Rowlings P.A., Lazarus H.M., Bolwell B.J., Freytes C.O., et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 2001, 19:406-413.
10. Czuczman M.S., Vose J.M., Witzig T.E., Zinzani P.L., Buckstein R., Polikoff J., et al. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 2011, 154:477-481.
11. Gisselbrecht C., Glass B., Singh Gill D., Linch D.C., Trneny M., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
12. Vellenga E., van Putten W.L., van 't Veer M.B., Zijlstra J.M., Fibbe W.E., van Oers M.H., et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008, 111:537-543.
13. Blay J., Gomez F., Sebban C., Bachelot T., Biron P., Guglielmi C., et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma group. Blood 1998, 92:3562-3568.
14. Hamlin P.A., Zelenetz A.D., Kewalramani T., Qin J., Satagopan J.M., Verbel D., et al. Age-adjusted international prognostic index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2003, 102:1989-1996.
15. Crump M, Kuruvilla J, Couban S, Macdonald D, Kukreti V, Kouroukis T, et al. Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) chemotherapy prior to autologous stem cell transplantation for relapsed and refractory aggressive lymphomas: final results of the randomized Phase III NCIC CTG study LY12. ASH annual meeting. Abstract #7452012; 2012.
16. Fernandez H.F., Escalon M.P., Pereira D., Lazarus H.M. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road. Bone Marrow Transplant 2007, 40:505-513.
17. Zhang M.M., Gopal A.K. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin Hematol 2008, 45:118-125.
18. Shimoni A., Avivi I., Rowe J.M., Yeshurun M., Levi I., Or R., et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012, 118:4706-4714.
19. Habermann T.M., Weller E.A., Morrison V.A., Gascoyne R.D., Cassileth P.A., Cohn J.B., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
20. Gisselbrecht C., Schmitz N., Mounier N., Singh Gill D., Linch D.C., Trneny M., et al. Rituximab Maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 2012.
21. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
22. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
23. Moskowitz C.H., Zelenetz A.D., Kewalramani T., Hamlin P., Lessac-Chenen S., Houldsworth J., et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL. Blood 2005, 106:3383-3385.
24. Thieblemont C., Briere J., Mounier N., Voelker H.U., Cuccuini W., Hirchaud E., et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011, 29:4079-4087.
25. Barrans S., Crouch S., Smith A., Turner K., Owen R., Patmore R., et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010, 28:3360-3365.
26. Cuccuini W., Briere J., Mounier N., Voelker H.U., Rosenwald A., Sundstrom C., et al. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood 2012, 119:4619-4624.
27. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
28. Barton S., Hawkes E.A., Wotherspoon A., Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks. Oncologist 2012, 17:1562-1573.
29. Zhang Y., Zhao X., Tao J. Epigenetics, c-Myc and aggressive B-cell lymphomas. Oncotarget 2012.
30. den Hollander J., Rimpi S., Doherty J.R., Rudelius M., Buck A., Hoellein A., et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010, 116:1498-1505.
31. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011, 108:16669-16674.
32. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
33. Tsai P.C., Hernandez-Ilizaliturri F.J., Bangia N., Olejniczak S.H., Czuczman M.S. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res 2012, 18:1039-1050.
34. Reske T., Fulciniti M., Munshi N.C. Mechanism of action of immunomodulatory agents in multiple myeloma. Med Oncol 2010, 27(Suppl 1):S7-S13.
35. Witzig T.E., Vose J.M., Zinzani P.L., Reeder C.B., Buckstein R., Polikoff J.A., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011, 22:1622-1627.
36. Piekarz R.L., Bates S.E. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res 2009, 15:3918-3926.
37. Crump M., Coiffier B., Jacobsen E.D., Sun L., Ricker J.L., Xie H., et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008, 19:964-969.
38. Crump M., Andreadis C., Assouline S., Rizzieri D., Wedgwood A., McLaughlin P., et al. Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: interim results from a phase II study. ASCO Meet Abstr 2008, 26:8528.
39. Witzig T.E., Reeder C.B., LaPlant B.R., Gupta M., Johnston P.B., Micallef I.N., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25:341-347.
40. Smith S.M., van Besien K., Karrison T., Dancey J., McLaughlin P., Younes A., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the university of Chicago phase II consortium. J Clin Oncol 2010, 28:4740-4746.
41. Advani R.H., Buggy J.J., Sharman J.P., Smith S.M., Boyd T.E., Grant B., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012.
42. Friedberg J.W., Sharman J., Sweetenham J., Johnston P.B., Vose J.M., Lacasce A., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115:2578-2585.
43. Castillo J.J., Furman M., Winer E.S. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs 2012, 21:15-22.
44. Mossner E., Brunker P., Moser S., Puntener U., Schmidt C., Herter S., et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010, 115:4393-4402.
45. Tay K., Dunleavy K., Wilson W.H. Novel agents for B-cell non-Hodgkin lymphoma: science and the promise. Blood Rev 2010, 24:69-82.
46. Carnahan J., Stein R., Qu Z., Hess K., Cesano A., Hansen H.J., et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 2007, 44:1331-1341.
47. Advani A., Coiffier B., Czuczman M.S., Dreyling M., Foran J., Gine E., et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010, 28:2085-2093.
48. Matasar M.J., Czuczman M.S., Rodriguez M.A., Fennessy M., Shea T.C., Spitzer G., et al. A Phase II study of ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory aggressive B-cell lymphoma prior to autologous stem cell transplantation (ASCT). ASH Ann Meet Abstr 2011, 118:957.
49. Hernandez-Ilizaliturri F.J., Deeb G., Zinzani P.L., Pileri S.A., Malik F., Macon W.R., et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011, 117:5058-5066.
50. Vose J., Armitage J., Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124-4130.
51. Abouyabis A.N., Shenoy P.J., Sinha R., Flowers C.R., Lechowicz M.J. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011, 2011:623924.
52. Armitage J.O., Hsi E.D., Foss F.M. Clinical roundtable monograph. T-cell lymphoma: therapeutic overview and disease state awareness. Clin Adv Hematol Oncol 2010, 8:1-15.
53. Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. Adv Hematol 2010, 2010:320624.
54. Cosenza M., Civallero M., Grisendi G., Marcheselli L., Roat E., Bari A., et al. Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines. Ann Hematol 2012, 91:1613-1622.
55. O'Connor O.A., Pro B., Pinter-Brown L., Bartlett N., Popplewell L., Coiffier B., et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011, 29:1182-1189.
56. Coiffier B., Pro B., Prince H.M., Foss F., Sokol L., Greenwood M., et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012, 30:631-636.
57. Piekarz R.L., Frye R., Prince H.M., Kirschbaum M.H., Zain J., Allen S.L., et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011, 117:5827-5834.
58. Oki Y., Younes A. Brentuximab vedotin in systemic T-cell lymphoma. Expert Opin Biol Ther 2012, 12:623-632.
59. Pro B., Advani R., Brice P., Bartlett N.L., Rosenblatt J.D., Illidge T., et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012, 30:2190-2196.
60. Gambacorti-Passerini C., Messa C., Pogliani E.M. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 2011, 364:775-776.
61. Leonard J.P., Coleman M., Ketas J.C., Chadburn A., Furman R., Schuster M.W., et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004, 10:5327-5334.
62. Sehn L.H., Assouline S.E., Stewart D.A., Mangel J., Gascoyne R.D., Fine G., et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 2012, 119:5118-5125.
63. Coiffier B., Bosly A., Wu K.L., Verhoef G., Koen V.E., Martinelli G., et al. Ofatumumab monotherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a multicenter Phase II study. ASH Ann Meet Abstr 2010, 116:395.
64. Strauss S.J., Morschhauser F., Rech J., Repp R., Solal-Celigny P., Zinzani P.L., et al. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006, 24:3880-3886.
65. Wagner-Johnston N., Goy A., Rodriguez M.A., Ehmann C., Hamlin P., Radford J., et al. Anti-CD22 immunoconjugate inotuzumab ozogamicin + rituximab followed by stem cell transplantation in relapsed/refractory DLBCL patients: safety and efficacy. ASH Ann Meet Abstr 2011, 118:2718.
66. Zinzani P.L., Pellegrini C., Gandolfi L., Stefoni V., Quirini F., Derenzini E., et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma, Myeloma Leukemia 2011, 11:462-466.